Detalhe da pesquisa
1.
Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.
Pharm Res;
40(9): 2133-2146, 2023 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37704893
2.
Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology.
J Am Chem Soc;
141(39): 15700-15709, 2019 10 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31497954
3.
Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.
Blood;
122(9): 1599-609, 2013 Aug 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23861246
4.
Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
J Med Chem;
67(7): 5866-5882, 2024 Apr 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38556760
5.
Moderate aplastic anemia in children: preliminary outcomes for treatment versus observation from a single-institutional experience.
J Pediatr Hematol Oncol;
35(2): 148-52, 2013 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23128338
6.
Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma.
J Pediatr Hematol Oncol;
35(5): e209-13, 2013 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23619105
7.
TAM family kinases as therapeutic targets at the interface of cancer and immunity.
Nat Rev Clin Oncol;
20(11): 755-779, 2023 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37667010
8.
Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis.
Sci Rep;
13(1): 12556, 2023 08 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37532715
9.
Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
Front Immunol;
14: 1146721, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36960055
10.
Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia.
Genome Med;
15(1): 83, 2023 10 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37845689
11.
In vitro vascular differentiation system efficiently produces natural killer cells for cancer immunotherapies.
Oncoimmunology;
12(1): 2240670, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37720687
12.
Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML.
bioRxiv;
2023 Mar 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36993676
13.
Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia.
Nat Commun;
14(1): 6209, 2023 10 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37798266
14.
Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
J Control Release;
361: 470-482, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37543290
15.
MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
J Clin Invest;
132(15)2022 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35708914
16.
Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening.
Adv Mater;
34(10): e2108084, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34989049
17.
Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.
Cancers (Basel);
14(24)2022 Dec 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36551626
18.
Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia.
Nat Commun;
13(1): 1157, 2022 03 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35241678
19.
Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.
JCO Precis Oncol;
6: e2100451, 2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35544730
20.
Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria.
Mol Genet Metab;
103(4): 330-7, 2011 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21601502